International Clinical Trial: A phase IIa, randomized, open-label, blinded endpoint evaluation study of early administration of evolocumab after thrombolysis in patients with atherosclerotic acute ischemic stroke

Geneva, Jan. 12 -- International Clinical Trials Registry received information related to the study (ChiCTR2500115300) titled 'A phase IIa, randomized, open-label, blinded endpoint evaluation study of early administration of evolocumab after thrombolysis in patients with atherosclerotic acute ischemic stroke' on Dec. 24, 2025.

Study Type: Interventional study

Study Design: Case-Control study

Primary Sponsor: The Affiliated Hospital of Xuzhou Medical University

Condition: Acute ischemic stroke

Intervention: Intervention group:Intravenous thrombolysis + subcutaneous injection of Eryuomid 420 mg (3 syringes, 140 mg each) within 24 hours after thrombolysis + oral Atorvastatin 20 mg/day

Recruitment Status: Recruiting

Phase: N/A

Da...